Cantor Fitzgerald raised the firm’s price target on MiMedx (MDXG) to $12 from $11 and keeps an Overweight rating on the shares following the company reporting a Q2 revenue beat and raising 2025 revenue guidance. Given the firm’s belief that MiMedx and Organogenesis (ORGO) are positioned to take market share in 2026 and represent undervalued opportunities, it would be buyers amid the share’s strength.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDXG: